Investor Presentaiton

2030 2023 Developing medicines in rapidly growing markets with significant commercial opportunities Oncology Hematology Immunology Cardiovascular* Neuroscience $85B+ $49B+ $60B+ $30B+ $23B+ $140B+ $90B+ $75B+ $21B+ $38B+ Ill Bristol Myers Squibb *CV markets impacted by generic entry in Atrial Fibrillation Source: EvaluatePharma estimates Not for Product Promotional Use 140

View entire presentation